Role of gastrointestinal hormones in postprandial reduction of bone resorption

DB Henriksen, P Alexandersen…�- Journal of Bone and�…, 2003 - academic.oup.com
Collagen type I fragments, reflecting bone resorption, and release of gut hormones were
investigated after a meal. Investigations led to a dose escalation study with glucagon like�…

Disassociation of bone resorption and formation by GLP-2: a 14-day study in healthy postmenopausal women

DB Henriksen, P Alexandersen, B Hartmann…�- Bone, 2007 - Elsevier
We have previously shown that a single subcutaneous injection of glucagon-like peptide-2
(GLP-2) at 10 pm in postmenopausal women results in a dose-dependent decrease in the�…

Reduction of nocturnal rise in bone resorption by subcutaneous GLP-2

DB Henriksen, P Alexandersen, I Byrjalsen…�- Bone, 2004 - Elsevier
We have previously shown that a subcutaneous injection of glucagon-like peptide-2 (GLP-2)
at 9 am in fasting postmenopausal women results in a dose-dependent decrease in the�…

GIP and GLP-2 together improve bone turnover in humans supporting GIPR-GLP-2R co-agonists as future osteoporosis treatment

MBN Gabe, K Skov-Jeppesen, LS Gasbjerg…�- Pharmacological�…, 2022 - Elsevier
The intestinal hormones glucose-dependent insulinotropic polypeptide (GIP) and glucagon-
like peptide-2 (GLP-2) are key regulators of postprandial bone turnover in humans. We�…

Glucose-dependent insulinotropic polypeptide inhibits bone resorption in humans

A Nissen, M Christensen, FK Knop…�- The Journal of�…, 2014 - academic.oup.com
Background: In humans, the pronounced postprandial reduction in bone resorption
(decreasing bone resorption markers by around 50%) has been suggested to be caused by�…

Glucose-dependent insulinotropic polypeptide (GIP) inhibits bone resorption independently of insulin and glycemia

MB Christensen, A Lund, S Calanna…�- The Journal of�…, 2018 - academic.oup.com
Context The gut hormone glucose-dependent insulinotropic polypeptide (GIP) causes
postprandial insulin release and inhibits bone resorption assessed by carboxy-terminal�…

Four-month treatment with GLP-2 significantly increases hip BMD: a randomized, placebo-controlled, dose-ranging study in postmenopausal women with low BMD

DB Henriksen, P Alexandersen, B Hartmann…�- Bone, 2009 - Elsevier
We have previously shown that repeated dosing of glucagon-like peptide-2 (GLP-2) at 10
pm in postmenopausal women for 14 days results in a dose-dependent decrease in the�…

GLP-2 and GIP exert separate effects on bone turnover: a randomized, placebo-controlled, crossover study in healthy young men

K Skov-Jeppesen, MS Svane, C Martinussen…�- Bone, 2019 - Elsevier
Abstract Background Glucagon-like peptide-2 (GLP-2) and glucose-dependent
insulinotropic polypeptide (GIP) both inhibit bone resorption in humans but the underlying�…

Short-term administration of glucagon-like peptide-2. Effects on bone mineral density and markers of bone turnover in short-bowel patients with no colon

KV Haderslev, PB Jeppesen, B Hartmann…�- Scandinavian Journal�…, 2002 - Taylor & Francis
Background: Glucagon-like peptide 2 (GLP-2) is a newly discovered intestinotrophic
hormone. We have recently reported that a 5-week GLP-2 treatment improved the intestinal�…

Effect of GLP-1 treatment on bone turnover in normal, type 2 diabetic, and insulin-resistant states

B Nuche-Berenguer, P Moreno, P Esbrit…�- Calcified tissue�…, 2009 - Springer
It has been suggested that hormones released after nutrient absorption, such as glucose-
dependent insulinotropic peptide (GIP) and glucagon-like peptide 2 (GLP-2), could be�…